HC Wainwright Rates Neumora Therapeutics (NMRA) buy
HC Wainwright maintains its buy rating on NMRA with a $7 target, a 665.86% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Neumora Therapeutics, Inc. ($NMRA) "buy" with a $7 price target on June 16, 2026.
Since the rating, $NMRA is up 3.2% after 1 week, up 2.6% after 1 month and down 69.9% to date (from the $1.56 close on Jun 16, 2026).
NMRA
Neumora Therapeutics, Inc.
Key Points
- On June 16, 2026, HC Wainwright reiterated its buy rating on NMRA, setting a price target of $7.
- HC Wainwright's $7 price target implies 665.86% upside from Neumora Therapeutics, Inc.'s ($NMRA) current $0.91 share price.
- NMRA shares are trading around $0.91, reflecting a diverse range of institutional activities and insider transactions.
- Recent insider buying involved multiple executives acquiring 80,000 shares each, while institutional investors showed mixed activity.
Get $NMRA trade alerts by text
We text you when insiders, Congress or big funds trade $NMRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neumora Therapeutics, Inc. alert may contain errors. Disclosures
On June 16, 2026, HC Wainwright reiterated its buy rating on NMRA, maintaining a price target of $7. This decision comes as NMRA shares trade near $0.91, suggesting potential upside according to the firm's analysis.
Other Institutional Activity in NMRA
SIREN, L.L.C. increased its holdings in NMRA by 2,209,039 shares, ending with 8,497,822 shares valued at approximately $16.57 million. In contrast, SoftBank Group Corp. trimmed its position by 339,419 shares, holding 6,090,301 shares worth about $11.88 million. Perceptive Advisors LLC took a new position with 5,104,097 shares valued at $9.95 million, while MIC Capital Management UK LLP kept its stake unchanged at 4,460,700 shares, valued at $8.70 million. Vanguard Capital Management LLC also initiated a new position, acquiring 3,891,893 shares valued at $7.59 million.
Neumora Therapeutics, Inc. Stock Up 25.2%
Shares of NMRA are currently trading around $0.91. The stock's recent institutional activities and analyst ratings reflect varying perspectives on its potential value. The company's market performance will be closely watched by investors, especially in light of these new recommendations and position changes.
$NMRA price target
Neumora Therapeutics, Inc. daily closes and this analyst's $7 target. Not advice.
Insider Buying and Selling at Neumora Therapeutics, Inc.
On May 27, 2026, several insiders, including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad, each purchased 80,000 shares of NMRA. These transactions were not part of a prearranged trading plan. Earlier in the year, on February 17, 2026, Michael Lee Milligan, NMRA's Chief Financial Officer and Principal Accounting Officer, sold 1,436 shares at an average price of $3.56.
Analysts Set New Price Targets
On June 16, 2026, HC Wainwright & Co. maintained its buy rating for NMRA with a $7 price target. Previously, on March 31, 2026, Guggenheim and Needham both reiterated their buy ratings, setting targets at $14 and $8, respectively. RBC Capital had upgraded NMRA to a buy rating with a $7 target on December 1, 2025. The consensus among analysts is a buy rating, with a mean target price reflecting optimism about NMRA's future prospects.
Bottom Line
HC Wainwright's reiterated buy rating and $7 target for NMRA highlight the firm's confidence in the stock's potential. Investors track these ratings and insider transactions to gauge market sentiment and potential future performance. As always with 13F filings and analyst ratings, these insights are based on past data and projections, and actual market conditions may vary.
Related Filing Alerts
Source: HC Wainwright's rating change on $NMRA (Jun 16, 2026). Written by software, not financial advice. How we make alerts